Post by Tony Crispino on May 29, 2016 11:10:48 GMT -8
We are approaching our 4th year with clinical trial S1216. We have three subsets in the trial that are testing Circulating Tumor Cell (CTC) enumeration, sequencing, and gene expression. We are delighted to release early findings on CTC enumeration.
ASCO Abstract 2016: Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).
"Conclusions: In this phase 3 trial, the largest prospective CTC cohort in mHSPC to date, baseline CTCs were detected in >1/3 of patients and nearly half of patients who had not yet initiated therapy. Presence of CTCs was associated with known baseline prognostic factors and therefore may predict clinical outcome with continued follow-up. Further CTC enumeration, sequencing and gene expression are ongoing in S1216 to maximize the prognostic and predictive benefit of CTC analysis in mHSPC."
The clear signal is that the higher the CTC counts the less responsive the disease to treatment and the more likelihood for disease progression. This was done prospectively and is the largest cohort to date testing CTC's. Our findings will be presented at ASCO next week and will indeed be received well.
With the CHAARTED trial showing marked improvement in overall survival with early chemotherapy, we know little about who would respond well and who would not in that trial. There is good reason to look at CTC's as a possible indicator in future patients. We'll know more as time moves on. With the release of CHAARTED, S1216 was modified to allow for early chemotherapy and we hope to report more on CTC's in those patients as a new subset.
S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC) (NCT01809691).
ASCO Abstract 2016: Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).
"Conclusions: In this phase 3 trial, the largest prospective CTC cohort in mHSPC to date, baseline CTCs were detected in >1/3 of patients and nearly half of patients who had not yet initiated therapy. Presence of CTCs was associated with known baseline prognostic factors and therefore may predict clinical outcome with continued follow-up. Further CTC enumeration, sequencing and gene expression are ongoing in S1216 to maximize the prognostic and predictive benefit of CTC analysis in mHSPC."
The clear signal is that the higher the CTC counts the less responsive the disease to treatment and the more likelihood for disease progression. This was done prospectively and is the largest cohort to date testing CTC's. Our findings will be presented at ASCO next week and will indeed be received well.
With the CHAARTED trial showing marked improvement in overall survival with early chemotherapy, we know little about who would respond well and who would not in that trial. There is good reason to look at CTC's as a possible indicator in future patients. We'll know more as time moves on. With the release of CHAARTED, S1216 was modified to allow for early chemotherapy and we hope to report more on CTC's in those patients as a new subset.
S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC) (NCT01809691).